These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-000353-38 A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence 2012-10-31 bad-data
Listed as ongoing, but also has a completion date 2006-005314-12 A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evalu... 2010-02-25 bad-data
Not reported 2007-006078-27 A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS. CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVE METASTATIC BREAST CANCER 2013-06-15 due-trials
Exempt Terminated 2011-003408-19 A Phase I/II, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the MEK inhibitor WX-554 in patients with solid tumours 2014-03-28 not-yet-due